- Coordinator
- Eibir Gemeinnutzige GmbH Zur Forderung Der Erforschung Der Biomedizinischen Bildgebung, Austria
- Runs
- 1 January 2023 to 31 December 2027
- Status
- Running
- EU funding
- €8.7m
- Total cost
- €8.7m
- Partners
- 13 organisations in 8 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101057091
What the project is doing
In the project's own words, from its summary on CORDIS.
ArtifArtificial Intelligence (AI) will revolutionize healthcare as its diagnostic performance approaches that of clinical experts. In particular, in cancer screening, AI helps patients to make better-informed decisions and reduce medical error. However, this requires large datasets whose collection faces severe practical, ethical and legal obstacles. These obstacles can be overcome with swarm learning (SL) where partners jointly train AI models without sharing any data.
Yet, access to SL technology is seriously limited because no studies have implemented SL in a true multinational setup, no practically usable implementation of SL is available, researchers & healthcare providers have no experience with setting up SL networks and policymakers are currently unaware of the broader implications of SL. ODELIA will address & solve these issues: ODELIA will build the first open-source software framework for SL, providing an assembly line for the streamlined development of AI solutions.
To serve as a blueprint for future SL-based AI systems, ODELIA partners collaborate as a swarm to develop the first clinically useful AI algorithm for the detection of breast cancer in magnetic resonance imaging (MRI). The size of ODELIA's distributed database will exceed all previous studies and ODELIA's AI models will reach expert-level performance for breast cancer screening. Thereby, ODELIA will not only deliver a useful medical application, but prove the clinical benefit of SL in terms of accelerated development, increased performance and robust generalizability to ultimately save thousands of lives of European patients.
ODELIA's success will push partners to serve as nuclei for the exponential growth of the SL network and extend SL to a multitude of medical applications. Thus, patients, healthcare providers and citizens in Europe will be provided with a digital infrastructure that enables development of expert-level AI tools on big data without compromising data safety and data privacy.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Eibir Gemeinnutzige GmbH Zur Forderung Der Erforschung Der Biomedizinischen Bildgebung | Wien | Austria | Coordinator |
| Osimis | Liege | Belgium | Participant |
| Universitat Zurich | Zurich | Switzerland | Associatedpartner |
| Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eV | Munchen | Germany | Participant |
| Stratifai GmbH | Berlin | Germany | Participant |
| Technische Universitaet Dresden | Dresden | Germany | Participant |
| Universitaetsklinikum Aachen | Aachen | Germany | Participant |
| Diagnostikon Kai Therapeftikon Kentron Athinon Ygeia Anonymos Etaireia | Marousi | Greece | Participant |
| Fundacio Privada Institut D'investigacio Oncologica De Vall-Hebron (vhio) | Barcelona | Spain | Participant |
| Ribera Salud SA | Valencia | Spain | Participant |
| Stichting Radboud Universitair Medisch Centrum | Nijmegen | Netherlands | Participant |
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Participant |
| The Chancellor Masters and Scholars of the University of Cambridge | Cambridge | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI